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Abstract 
The allylation of indirubin produced the expected indolic N'-allylindirubin and N,N'-diallylindirubin 
derivatives in moderate yields, together with the corresponding N-substituted isatin products. At higher 
temperatures, the base-initiated reaction with allylic halides yielded spiroindolinepyrido[1,2-
a]indolediones in a one-pot cascade reaction sequence with yields of up to 70%. These readily accessed, 
new spiro compounds represent the first reported examples of indirubin participating in cascade reactions. 
Preliminary in vitro biological testing of some of the products indicated promising activity against some 
cancer cell lines and against Plasmodium falciparum for two spiro derivatives. Computational methods 
were used to gain a greater understanding of the UV/Vis spectroscopic data for the N'-substituted and 
N,N'-disubstituted indirubin derivatives. 
1. Introduction 
The search for new molecular entities, especially easily accessible complex heterocycles, is of significant 
interest in the exploration of new bioactive compounds and in materials chemistry. Often, cascade 
reactions are used to realize such synthetic targets starting with small molecules and utilizing them in 
complex multistep reactions. Our recent contributions to this field have focused on a notable variation to 
this strategy in that we started with a larger, but abundant and cheap molecule, the dye indigo 1 (Figure 
1). Indigo afforded a unique opportunity in providing an advanced starting material for the potential rapid 
synthesis of the diindolic system of natural product analogs. To this end, we recently reported the first 
cascade reactions of indigo via base-initiated allylation and propargylation, producing unexpected 
polyheterocyclic compounds (Figure 1) in multistep reactions. This surprising result revealed a new arena 
in the previously unreported chemistry of indigo, allowing access to unique, relatively complex 
heterocycles in one pot.1-3 
The structural isomers of indigo 1, indirubin 2 and isoindigo 3 (Figure 2), are known,4 but knowledge of 
their chemistry is still limited. Indirubin is the most well studied due to the reported biological activity of 
derivatives, known to suppress the metastatic ability of human head and neck cancer cells5 and to reduce 
the invasion of glioma cells both in vitro and in vivo.6 Further examples include inhibition of cyclin-
dependent kinases7 and glycogen synthase kinase-3, the latter being linked to Alzheimer’s disease.8 
Figure 1: Selected examples of heterocycles produced via the cascade 
reactions of indigo using either allyl bromide or propargyl bromide and base. 
 
Indirubin also inhibits intersegmental vessel growth and induces cellular apoptosis in an in vivo zebrafish 
model9 while other indirubin derivatives or analogues,10 including N-glycosides, show antiproliferative 
activity against a number of human cancer cell lines.11,12 Other effects of indirubin or derivatives include 
anti-protozoal activity13 as well as inhibition of lipoxygenase.14 Isoindigo, its derivatives and analogues, 




















Figure 2. Indigo 1 and its structural isomers indirubin 2 and isoindigo 3. 
 
Equally important is the basic chemistry of indirubin, including reaction at the carbonyl group, e.g. oxime 
formation,18 which often leads to an increase in biological activity, attack by Grignard reagents19 and 
substitution reactions at the amide functionality.20 An isoindigo derivative has also been shown to provide 
an advanced starting template for total synthesis, e.g. the use of the 2,2'-double bond in N-tosylisoindigo 
as a dienophile in a key early Diels˗Alder reaction to build up molecular complexity with stereochemical 
control in synthetic studies toward the anti-leukemic marine alkaloid communesin F.21 
Therefore, given the recent understanding of cascade reactions of indigo 1, we investigated the possibility 
of analogous cascade reactions of indirubin 2 and their potential to generate new heterocycles in one pot. 
These results are disclosed in this paper together with some initial in vitro antiplasmodial, 

































2. Results and Discussion 
2.1. Synthesis and Product Identification 
Initial reactions with indirubin were performed as per the allylation of indigo.1 In a typical reaction, a 
solution of indirubin in DMF with caesium carbonate was sonicated for 30 min to aid solubility and anion 
formation. The reaction was heated to 70 °C followed by the addition of the allyl bromide and heated for 
16 hours. The outcomes of these reactions are summarized in Scheme 1. The use of the allyl bromide 
gave a 10% yield of the known22 oxidative cleavage product N-allylisatin (Type A), together with the 
pink mono oxindolic N-allylated indirubin 9 (Type B) and the deep blue diallylindirubin 14 (Type C) in 
24% and 19% yields, respectively. This initial reaction indicated that indirubin is significantly less 
reactive than the corresponding indigo. The use of substituted allyl bromides continued the trend with the 
pink mono allylated derivatives (Type B) being produced in yields from 20-49% in 16 hour reactions 
(entries 1-4), with an extended 20 hour reaction required to produce the N'-cinnamylindirubin 13 (21%). 
The diallylated indirubins (Type C) were also produced in the same reactions in yields of 3-30% although 
these ratios are somewhat misleading due to the variable stability of the Type C compounds under the 
reaction conditions, e.g. with cinnamyl bromide and a 4 hour reaction time the N,N'-dicinnamylindirubin 
18 was isolated in an 11% yield (entry 6), but in a 20 hour reaction, the major outcome was the Type B 
N'-cinnamylindirubin 13. The instability of Type C molecules presumably to arises from removal of the 
stabilizing H···OC H-bond once all NH functionality is substituted. Also, in contrast to the that observed 
with indigo,1,2 no final O-allylated indirubin derivatives were observed. Further, no indirubin remained at 
the end of the reactions suggesting that compared to indigo, initial alkylation is easier (to the non-H-
bonded N'H) but the resulting molecules are less reactive than indigo to subsequent cascade reactions. 
 Calculated distances and angles  1H NMR shifts (ppm) 
 Parameter 
NH'···O=C 
A and α 
H4'··O=C 
B and β 
ΔE kJ/molc NH ArH4' 
2 
Dist. (Å) 2.04 2.21 
57.7 11.00a^ 8.76a 
angle (º) 124.3 120.3 
9 
Dist. (Å) 2.03 2.21 
61.6 10.53b 8.89b 
angle (º) 124.2 120.1 
14 
Dist.(Å) - 2.15 
36.1 - 8.63b 
angle (º) - 117.7 
a in DMSO-d6; 
b in CDCl3;
 c ΔE: Energy difference between E and Z isomers; ^ both NH signals are assigned to the broad peak at 11.00 ppm 
Figure 3. The Z-isomer of indirubin (2), N'-allylindirubin (9) and, N,N'-diallylindirubin (14): Illustrated on 9 – the 
calculated angles are indicated by dashed lines, distances are indicated by arrows. NH1--O=C2' distances and angles as well as 
ArH4'--O=C3 distances and angles and the corresponding 1H NMR shifts of indirubin (2), N'-allylindirubin (9) and N,N'-
diallylindirubin (14). Calculated data are obtained using Hartree-Fock theory after optimization at the 6-31G* level. 
The 1H NMR spectrum of 9 indicated peaks at 4.46 ppm (d, J = 5.5 Hz), 5.22 ppm (s), 5.25 ppm (d, J = 
5.0 Hz) and 5.86-5.92 ppm (m), assigned to a single N-allyl substituent, as quantified by its relative 
integration to the indirubin aromatic protons. A single signal at 10.53 ppm was assigned to the NH, 
positioned downfield due to its H-bonding with the indirubin carbonyl. This also indicated that the allyl 
substituent was positioned on the N'-atom. Measurement of the HRMS (ESI) gave 303.1143, indicative of 
a molecular formula of C19H15N2O2, providing evidence for the presence of only a single allyl moiety. 
Analysis of the 1H NMR spectra of 14 showed an absence of a peak in the ~10.5 ppm region suggesting 
the loss of an NH moiety. The integration of the peaks assigned to the allyl substituent (e.g. 4.43 ppm 
(2H) and 4.82 ppm (2H) relative to the total number of peaks assigned to the indirubin H-atoms indicated 
a ratio of indirubin:allyl substituents to be 1:2. Further, the measured HRMS (ESI) of 14 relayed a 
molecular formula of C22H19N2O2. In other base-induced N-alkylation reactions of indirubin by simple 
alkyl halides, preferential alkylation of the oxindolic nitrogen was also observed.23 
In order to assess whether either the mono- or di-allylated products had undergone isomerization during 
the reaction process to form the 2,3'-E products (with a syn disposition of the carbonyl groups), and to 
support the product identifications, we undertook a series of computational experiments to characterize 
the monallylindirubin 9 and the diallylindirubin 14. 
Calculated distances (NH1···O=C2') and angles (N-H···O) between the amine group and the proximal 
carbonyl oxygen in indirubin (2) and its N'-allylated (9) and N,N'-diallylated (14) derivatives highlight the 
hydrogen bond character (Figure 3). Additionally, the distance (H4···O=C3) and angle (C-H···O) 
between the aromatic hydrogen H4' and the proximal carbonyl group are in accordance with the 
remarkable 1H NMR downfield shift of the aromatic hydrogen H4' and indicate the strong interaction 
(“H-bond”) of H4' with the proximal carbonyl group. 
The initial reaction product results at 70 °C clearly indicated a lower reactivity of indirubin to subsequent 
cyclisation. Therefore, in an attempt to force potential cascade reactions, the reactions were repeated at 
110 °C (Scheme 1, entries 7-12). This gave rise to the new spiroindolinepyrido[1,2-a]indoledione 
heterocycles of the type D in up to 70% yield in the case of allyl bromide (entry 7), arising from the 
introduction of three allylic moieties; at 70 °C, 19 (see also Figure 4) was isolated in only 2% yield. The 
1H NMR of 19 showed a ddd centred at 2.06 ppm with J = 18.3, 5.3 and 1.8 Hz, assigned to the sp2 
alkenyl H8'a - the corresponding H8'b was assigned to the dt (J = 18.3, 1.8 Hz) at 3.00 ppm. The signals 
assigned to H6' and H7' are contained within multiplets at 7.00 - 7.06 and 5.02 - 5.41 ppm respectively. 
The signal in the 13C NMR spectra at 48.0 ppm was assigned to the spiro C3, and the C2 amide carbonyl 
was assigned to the peak at 175.6 ppm whereas the peak at 199.1 ppm was attributed to the C10' carbonyl. 
Confirmation of the molecular formula of 19 was provided by analysis of the HR ESI mass spectrum 











 A B C D Y 
1 70 16 H H H 4 (10%) 9 (24%) 14 (19%) 19 (2%)  
2 70 16 Me H H 5 (3%) 10 (20%) 15 (30%)   
3 70 16 H Me H 6 (trace) 11 (49%) 16 (9%)   
4 70 16 H Me Me 7 (trace) 12 (29%) 17 (3%)   
5 70 20 H Ph H  13 (21%)    
6 70 4 H Ph H   18 (11%)   
7 110 6 H H H    19 (70%)  
8 110 6 Me H H  10 (10%)  20 (37%) 
 
9 110 6 H Me H    21 (24%)† 
 
10 110 6 H Me Me  12 (10%)    
11 110 6 H Ph H 8 (9%)   22 (8%) 
 
12 110 24 H Ph H    22 (13%) 
 
Scheme 1. The products of the reactions of indirubin 2 with a series of allyl bromides: Type A - isatin derivatives (4 - 8), Type 
B - N'-substituted indirubin derivatives (9 - 13), Type C - N,N'-disubstituted indirubin derivatives (14 - 18) and Type D - 
spiroindolinepyrido[1,2-a]indoledione derivatives (19 - 22). † Note: C-allyl substituent is not crotyl but has rearranged – see 
Figure 4 for details of structure. Trace indicates detected by TLC analysis at the completion of the reaction. # 3 Å sieves were 
additionally added to procedure B reactions. 
 
Analysis of the 1H NMR spectra of 21 revealed a dd at 5.03 ppm, assigned to the H7' olefin and multiplets 
at 7.08-7.16 and 3.40-3.47 ppm which were assigned to H6' and H8' within these peaks respectively 
(Figure 4). The terminal methyl group of the N-1-butenyl substituent was assigned to the doublet at 1.72 
ppm (J = 7.3 Hz) whereas the methyl substituent of the N-2-butenyl substituent was assigned to the 
doublet at 0.52 ppm (J = 8.0 Hz). The terminal olefinic methylene of this substituent was assigned to the 
doublet of doublets at 4.64 ppm (J = 10.0, 1.8 Hz) and 4.86 ppm (J = 17.0, 2.1 Hz) with the former in a 
cis orientation to the adjacent CH (multiplet at 5.72-5.89 ppm) and the latter in the relative trans 
orientation. These assignments indicated the presence of the C-methylallyl substituent, possibly formed 
by a rearrangement process after O-alkylation as discussed in the mechanistic section.  
The structures of the spiroindolinepyrido[1,2-a]indolediones 19, 20 and 21 were confirmed by single 
crystal X-ray crystallographic analysis, corroborating the C-allylic substituents and relative 




Figure 4. Crystal structures of the spiroindolinepyrido[1,2-a]indolediones 19, 20 and 21. 
 
There are reports24,25 of the synthesis of molecules with the same spiro heterocyclic skeleton to that in 19-
22, however these arose from reaction of skatole with 2-methylindole, followed by acylation in polar 
solvents – subsequent examination of the by-products revealed a spiro-type system, however, there was 
limited spectral evidence to support the proposed structures.  
The yields for the spiroindolinepyrido[1,2-a]indoledione systems from indirubin decrease with 
substitution of the allyl bromide, e.g. the yield drops to 37% with the additional methyl substituent at C2 
of the allyl moiety (entry 8) and down to 13% with the use of cinnamyl bromide (entry 12), this latter 
reaction requiring significantly longer reaction times (24 h) to achieve even this yield.  With a very bulky 
terminal gem-dimethyl group in the allylic bromide, no spiro-cyclization was observed. This trend is 
likely to arise from the steric impedance of the orthogonal spiro scaffold blocking the approach of the 
substituted allyl units during the installation of the C-allyl substituent (see Section 2.2 Mechanistic 
Proposals). Although the spiroindolinepyrido[1,2-a]indoledione 19, arising from addition of allyl 
bromide, was also observed in the reaction performed at 70 °C in a 2% yield (entry 1), no other examples 
were detected in reactions at this temperature (entries 2-6), probably indicative of the extra bulk of the 
substituted allyl moieties sterically impeding the spiro cyclisation. Further, in the 110 °C reactions 
(entries 7-12), there was no evidence of the presence of Type C products with Type B compounds 
probably reacting further at the higher temperature to the Type D products. The N-allylisatins were only 
detected in the 110 °C reactions in the case of the cinnamyl moiety (9%) at 6 h (entry 11). It is likely that 
the bulky cinnamyl unit lead to a slower reaction, allowing time for the oxidative cleavage to occur. The 
longer reaction times at higher temperatures probably resulted in further degradation in the reaction 
mixture. 
Along with these major products, minor fragmentation products were isolated including the anthranilate 
esters allyl 2-(allylamino)benzoate and 2-methylallyl 2-((2-methylallyl)amino)benzoate in very low yield 
from the respective allylation reactions at 110 °C and 70 °C. Structural elucidations of these esters arose 
from analysis of spectral data, with a diagnostic absorption band for the ester carbonyl group being 
apparent at 1673 cm-1 for the former and at 1682 cm-1 for the latter. 
For comparison purposes with the indigo substrate,3 reaction of propargyl bromide with indirubin in the 
presence of base at 70 °C for 16 hours only yielded N,N'-dipropargylindirubin 23 in low yield (13%) plus 
some (8%) of the isatin-derived anthranilate ester, prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate. 
2.2. Mechanistic Proposals 
The proposed mechanism for the 70 °C reactions proceeds with N-allylation on the oxindole ring 
producing the Type B compounds with a simple second allylation affording the Type C compounds 
(Scheme 2). In the 110 °C reactions, the diallylindirubin (Type C) upon O-protonation (tentatively with 
the weakly acidic bicarbonate ion as the proton source) and subsequent electron redistribution yields the 
intermediate ion X, which under base-catalysed conditions, undergoes cyclisation to form the spiro 
moiety (intermediate Y), with the C3' position activated by the conjugated protonation nitrogen atom. 
Subsequent O-allylation would generate the intermediate Z, a molecule not yet isolated from this 
reaction, as it is presumably converted rapidly to the isolated Type D spiro compounds. A number of 
possibilities exist for the mechanism converting Z to Type D compounds: a 1,3-Claisen rearrangement 
would yield the observed outcome for spirocycles 19 and 20, but not for 21 and 22. Similarly, a route via 
enolate anion formation followed by a direct C9a allylation process, while satisfactory for most examples, 
does not explain outcome 21. A possible unifying mechanism that explains all results is a thermally-
induced homolytic cleavage radical cleavage of the allyloxy group in Z to produce two highly stabilised 
radical species, which could then react through attack at C9a to afford 21.2 With the comparable cinnamyl 
product 22 it is likely that steric factors mitigate against the cinnamyl radical at the carbon bearing the 
phenyl group.  
The 13C NMR spectra for these heterocycles showed no duplication in peaks, consistent with the 
formation of a single enantiomeric pair out of the four possible diastereomers. The proposed mechanism 
is in accordance with this observation with the initial cyclisation to form the spiro atom likely to produce 
both possible stereoisomers as approach from either face would be equal. The generation of the second 
 
Scheme 2. Proposed mechanism towards the formation of the spiroindolinepyrido[1,2-a]indolediones 19 - 22. 
 
stereogenic atom occurs during the final rearrangement step and here, there is a clear facial discrimination 
with the approach of the allyl unit (probably an allylic radical species) from the less hindered carbonyl 
side. The higher temperature of 110 °C is required to drive the reaction through to the Type D spiro 
compounds, while at 70 °C, N-monoallylation and N,N'-diallyation products predominate. In a separate 
experiment, reaction of the N-monoallylated indirubin (9) with excess allyl bromide at 110 °C for 20 h, 
only produced a complex mixture with no indication of the spiroindolinepyridoindole heterocycle (14), 
presumably due to further reaction of this compound under the conditions. We observed that N,N'-
disubstituted indirubins were not stable in solution at room temperature under light exposure. When N,N'-
diallylindirubin was kept in dichloromethane for several days, its colour gradually changed from dark 
blue to reddish-yellow. It is known that indigo is stable against photoinduced Z -> E isomerisation due to 
its stabilizing NH hydrogen bonding, but substitutions on both nitrogens results in a loss of hydrogen 
bonding and leads to phototropic behaviour.26 The same loss of H-bonding may be the reason for the low 
stability of the disubstituted indirubins (c.f. Fig. 3): the Z configuration of indirubin and its N'-substituted 
derivatives exhibit stabilizing NH-mediated hydrogen bonds and are therefore inert against Z to E 
isomerisation, while this is not the case for the disubstituted indirubins and photoinduced Z to E 
isomerization occurs. 
The formation of the isatin based products can be rationalised in terms of oxidative cleavage with 
adventitious oxygen.22 Subsequent nucleophilic attack by allyl alcohol (formed from the bromide in the 
presence of carbonate) on the isatin C2-carbonyl and then addition to the C3 carbonyl, followed by 
fragmentation with loss of carbon dioxide and propene would give the minor anthranilate ester observed. 
2.3. Colour Properties 
Indirubin (2) as well as its N'-substituted derivatives (9-13) are red compounds with UV/Vis absorption 
maxima of about 536 nm and 533 nm in methanol whereas the N,N'-disubstituted derivatives (14-18) 
1. Cs2CO3














































without an  NH…OC hydrogen bond are blue and have a UV/Vis absorption maximum of about 575 nm 
in methanol. Selected data is given in Table 1. 
Calculated UV/Vis absorption maxima differ significantly from the experimental values but the increase 
in λmax from the N'-allylated to the N,N'-diallylated indirubin is predicted correctly with the Hartree Fock 
and DFT methodology. However, the calculated wavelengths using B3LYP theory are closer to the 
experimental wavelengths in comparison to Hartree-Fock theory. Taking into account the solvent effect, 
which leads to a bathochromic shift of the absorption maximum wavelengths the more polar the solvent 
used, the B3LYP results are acceptable as the calculated values are in vacuo (Table 2). In contrast to the 
indirubins, the spiroindolinepyrido[1,2-a]indoledione (19) is yellow, reflecting the absence of the 2,3'-
double bond and the consequent decrease in conjugation. In order to examine this further, the calculated 
UV/Vis absorption spectra in vacuo and experimentally obtained UV/Vis spectra of 19 were compared 
(Table 1). Again, density functional theory (B3LYP) correctly predicted the observed large decrease in 
λmax for 19 compared with 14. The predictive power of DFT has been well established by Jacquemin et al 
for indirubin, isoindigo and derivatives25,26 including the observation that better fits between theory and 
experiment occur when bulk solvent effects are included in the calculations. Further investigations are 
required to more fully examine this with compounds 9 and 14. 
The loss of a hydrogen bond should lead in theory to an increased energy difference between the ground 
state and the excited state and therefore to an UV/Vis absorption maximum at lower wavelengths.29,30 
However, the opposite is observed with the calculated values (2 to 9). This bathochromic shift can be 
explained by referring to the ‘cross-conjugated’ system (‘H-chromophore’), which was found to be an 
important feature to explain (although other explanations have been proposed31), the colour of indigoid 
molecules.32,33 It consists of a C=C double bond substituted with two electron donor groups (EDGs; in an 
anti configuration to each other) and two electron withdrawing groups (EWGs; in an anti configuration to 
each other). In indirubin and the N-allylated derivatives such a chromophore is present with the two 
carbonyl moieties as EWGs and an amino group and a fused aryl ring as electron donor groups. 
Calculations of the UV/Vis absorption maxima using B3LYP (after optimization at the 6-31G* level) on 
2, 9 and 14, as well as cut down oxopyrrolidinylideneindolinone theoretical model systems lacking one 
fused benzene ring, supported the significance of the H-chromophore in determining the colour of these 
systems (see Supplementary Information for the structures of the model systems and the full results). 
2.4. Biological Activity 
As indirubin and its derivatives are known to be active against various cancer cell lines, we screened our 
derivatives against a small number of cancer cell lines, namely small cell lung cancer (NCI-H187), KB-
oral cavity cancer and MCF-7 breast cancer, as well as testing for in vitro anti-TB (Mycobacterium 
tuberculosis, H37Ra strain) and anti-plasmodial (Plasmodium falciparum, K1 strain) activity. The results 
are summarized in Table 2. 
Table 1. Summary of experimentally obtained UV/Vis absorption maxima (spectra are measured in methanol) and 
calculated UV/Vis absorption maxima (spectra are calculated in vacuo) using B3LYP and Hartree Fock theory after 
optimization at the 6-31G* level. The numbers in between rows are the differences between absorption maxima for the 
respective compound pairs. 





 Hartree Fock 
indirubin (2) red 536 474 311 
  -3 +16 +6 
N'-allylindirubin (9) red 533 490 317 
  +44 +22 +18 
N,N'-diallylindirubin (14) blue 577 512 335 
  -151 -127 0 
spiroindolinepyrido[1,2-a]indoledione (19) yellow 426 385 335 
 
The isatin derivatives 4 and 5 showed modest, cytotoxic activity against the small cell lung cancer cell 
line but not against the other tested cancer cell lines, nor the mycobacterial or plasmodial strains. The N'-
substituted and N,N'-disubstituted indirubins show activities against the lung cancer cell line with the 
most potent compound being the mono diamethylallyl substituted derivative 12, with an IC50 value of 
0.66 μg/mL (2.0 µM) comparable to the positive controls ellipticine (1.47 μg/mL; 5.97 µM) and 
doxorubicin (0.077 μg/mL; 0.147 µM). A little surprisingly, compound 12 was inactive against the other 
two cancer cell lines. The most promising compound in the N,N'-disubstituted indirubin series was the 2-
methylallyl derivative 15, with activity against all three cancer cell lines, and being somewhat better than 
the positive controls against the rather refractory MCF-7 cell line; modest anti-TB activity in vitro was 
also apparent with this compound, while the disubstituted indirubin 16 was active in the anti-plasmodial 
assay. Although indirubin derivatives have been shown13 to inhibit the apicomplexan protozoal parasite 
Toxoplasma gondii, to the best of our knowledge anti-plasmodial activity of N,N'-disubstituted indirubins 
involving the apicomplexan Plasmodium falciparum has not been reported previously. However, 
derivatives with the isomeric isoindigo skeleton do show such inhibitory activity against P. falciparum.17 
Of the four spiroindolinepyrido[1,2-a]indolediones tested, anti-proliferative activity was seen only with 
compounds 19 and 22, although no clear SAR outcomes can be drawn from this limited series.  Promising 
anti-plasmodial activity in the low micromolar range was also seen with 19 and 22, and these compounds 
could serve as useful new leads for potential antimalarial drug development, with the incorporation of a 
spiro element in the framework of particular interest.34,35 
3. Conclusions 
We report here for the first time cascade reactions of indirubin through the reaction with allylic bromides 
in the presence of base. The initial reaction can be controlled to produce the pink-red N-monoallylated 
products, but the subsequent synthesis of the deep blue N,N'-diallylated indirubin was less successful due 
to the instability of the products. The cascade process begins when the reaction is heated to 110 °C – 
these are higher temperatures to induce the ongoing reaction process when compared to the reactions of 
Table 2. Anti-cancer, anti-tubercular, and anti-plasmodial activity of compounds  against three different cancer cell lines small 
cell lung cancer (NCI-H187), KB-oral cavity and MCF 7 breast cancer, all tested using a resazurin microplate assay (REMA), 
and an anti-TB (Mycobacterium tuberculosis, H37Ra strain), tested using a green fluorescent protein microplate assay 






















- - - - 
5 2.9 
(14.4) 
- - - - 
9 5.86 
(19.4) 
- - - - 
10 12.50 
(39.6) 
- - - - 
11 7.52 
(23.8) 
- - - - 
12 0.66 
(2.0) 
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Ellipticine 1.47 0.737    
Doxorubicin 0.077 0.504 7.97   
Tamoxifen   9.47   
Rifampicin    0.025  
Streptomycin    0.625  
Mefloquine     (0.0303) 
- = inactive. 
 
the related indigo where the cascade process completely consumes the starting material after 1 h at 88 
°C.2 Therefore, the indirubin molecule is more stable than indigo. The overall result of the cascade 
allylation of indirubin is the unexpected one-pot production of spiroindolinepyrido[1,2-a]indoledione 
heterocycles. This method provides simple access to these relatively complex structures with good 
diastereoselectivity. Importantly, this chemistry provides a facile route to the spirooxindole skeleton, a 
motif that is becoming increasingly important with the emergence of numerous examples both from 
nature and with biological activity.36-38 The results reported here highlight this importance with examples 
of derivatives which show significant activity as lead compounds against P. falciparum and micromolar 
activity against 3 different cancer cell lines. Therefore, this new chemistry of indirubin presents fresh 
possibilities to explore heterocyclic chemical space in a compact one-pot synthetic regime, which should 
be amenable to further generalisation.  
3.1. Experimental section 
3.2. General Methods 
DMF for dry reactions was obtained from a solvent purification system. Dichloromethane for extractions 
and column chromatography was distilled in air prior to use or HPLC grade dichloromethane was used, 
while other solvents were purchased reagent grade and used without further purification. Indirubin (2) 
was synthesized according to a literature procedure from isatin and 3-iodo-(1H)-indole.10 Reactions were 
carried out under nitrogen which was dried by passage through a 20 cm tube filled with CaCl2 or silica 
based drying agent, unless otherwise stated. Solvents were removed in vacuo on a rotary evaporator and 
products dried under high vacuum (~1 mbar) at room temperature. Flash column chromatography was 
performed using Merck flash silica gel 60 (63-200 mesh), particle size 40-63 μm, under a positive 
pressure of air. Preparative TLC (PTLC) was performed using Merck silica gel F254 pre-coated glass 
plates (20 x 20 cm) with a layer thickness of 500, 1000, 1500 or 2000 μm. 
Compounds were visualized under UV light (254 and 365 nm) using Merck silica gel F254 precoated 
aluminium plates. Melting points (Mp) were determined using a Gallenkamp (Griffin) melting point 
apparatus, are uncorrected and stated in degrees Celsius (°C). Infrared (IR) spectra were recorded with 
neat samples using a Nicolet Avatar 360 FT-IR spectrometer fitted with a Smart Omni-Sampler 
germanium crystal accessory. IR data is recorded in nanometers (nm) with peak intensity assigned as 
weak (w), medium (m) or strong (s). Low resolution mass spectra were obtained by electrospray 
ionisation (ESI) mass spectroscopy on a Micromass Platform LCZ spectrometer by injecting the samples 
as a solution in methanol. In some cases 1% HCOOH was added to suppress dimerization and/or aid in 
protonation. Alternatively, electron impact (EI) mass spectra were performed using a Shimadzu QP-5050 
spectrometer. High resolution mass spectrometry (HRMS) was performed using electrospray ionisation 
technique on a Waters QTOF Xevo spectrometer or electron impact technique on a Fison/VG Autospec-
TOF spectrometer at 70 eV with a source temperature of 250 °C. Ion mass charge (m/z) values of 
molecular ions (M), fragment peaks and adducts are stated with their relative abundances in parentheses. 
For compounds with more than one major isotope all significant isotopic peaks are reported. Proton (1H) 
and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded at 500 and 125 MHz 
respectively on a Varian Inova 500 MHz spectrometer or a VNMRS PS54 500 MHz spectrometer. 
Alternatively, 1H and 13C NMR spectra were recorded at 300 and 75 MHz respectively on a Varian 
Mercury 300 MHz spectrometer. All NMR shifts are reported in parts per million (ppm) and the δ values 
reported relative to a standardised value (standard in brackets). NMR data was acquired in CDCl3 (TMS, 
1H: δ = 0 ppm; CDCl3, 
13C: δ = 77.0 ppm), (CD3)2SO (DMSO, 
1H: δ = 2.50 ppm; (CD3)2SO, 
13C: δ = 39.5 
ppm), CD3OD (methanol, 
1H: δ = 3.31 ppm; CD3OD, 
13C: δ = 49.0 ppm) and (CD3)2CO (acetone, 
1H: δ = 
2.05 ppm; (CD3)2CO, 
13C: δ = 29.8 ppm). Coupling constants (J) are reported in Hertz (Hz) and refer to 
coupling between hydrogen nuclei over three bonds if one coupling constant is reported. If two coupling 
constants are reported, the smaller of the two refers to coupling between hydrogen nuclei over four bonds. 
Multiplicities are reported as singlet (s), broad singlet (bs), doublet (d), doublet of doublet (dd), triplet (t), 
doublet of triplet (dt), quartet (q), pentet (p), sextet, septet and multiplet (m). Assignment of carbons and 
protons for all compounds are based on the 1D and 2D NMR spectroscopic experiments APT, gCOSY, 
gHSQC, gHMBC and NOESY unless otherwise stated.  
UV/Vis spectra were obtained on dichloromethane solutions using a double beam UV-Vis-NIR 
spectrophotometer (Cary 500) operating between 300 – 1400 nm. All solutions were appropriately diluted 
with dichloromethane prior to analysis to fit within the absorbance limits of the detector, and placed into 
1 cm pathlength quartz cuvettes. All spectra were collected at room temperature. Sample sizes were 
between 1.000-2.000 mg, weighed with an accuracy of 6 decimal places using the seven figure balance 
CAHN C-35. Monosubstituted indirubin derivatives were diluted to 50.0 mL and all other indirubin 
derivatives to 25.0 mL The ε values reported have the units M-1cm-1. 
X-ray Structure Determination – images were measured on a Nonius Kappa CCD diffractometer 
(MoKα, graphite monochromator, λ = 0.71073 Å) and data extracted using the DENZO package.39 
Structure solution was by direct methods (SIR92).40 The structures were refined using the CRYSTALS 
program package.41 Atomic coordinates, bond lengths and angles, and displacement parameters for 
compounds 19, 20 and 21 have been deposited at the Cambridge Crystallographic Data Centre (CCDC 
1048189-1048191). These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_request/cif, 
by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 
Computational Methods 
Geometry Optimisations. The calculations were performed in vacuo throughout using the Spartan 
package 2010 (V1.1.0) as the calculation tool and the geometry of the molecule in the ground state was 
optimized using Hartree-Fock (HF) theory and the 6-31G* basis set. 
UV/Vis spectra. The Spartan package 2010 (V1.1.0) was used as the tool to calculate the spectra of the 
molecules in the ground state using either density functional theory and the hybrid functional B3LYP or 
HF theory after geometry optimisation with the 6-31G* basis set. 
  
3.3. Synthesis  
Synthetic Note: All potentially chiral compounds in this work were isolated or used as racemates. 
3.3.1. General Procedure A. 
A suspension of indirubin (1.0 eq.) in anhydrous DMF (20 mL) was sonicated for 5 min. To the stirred 
solution was added caesium carbonate (2.4 eq.) and the reaction mixture was heated to 70 °C. Allylic 
bromide (or derivative) (2.9 eq.) was added and the reaction mixture was stirred for the specified time at 
70 °C. The mixture was filtered while hot, washed with a little DMF and the filtrate concentrated under 
reduced pressure. The crude residue was subjected to flash silica gel column chromatography (100% 
petroleum spirit to CH2Cl2/petroleum spirit 4:1). 
3.3.1.1. N'-Allylindirubin (9); N,N'-diallylindirubin (14); N-allylisatin (4).   
Following the general procedure A, a suspension of indirubin (202 mg, 771 μmol) in DMF (20 mL) was 
heated with caesium carbonate (603 mg, 1.85 mmol) and allyl bromide (193 μL, 2.24 mmol) for 16 h to 
obtain N'-allylindirubin (9) (56.1 mg, 24%) as a red solid. Mp 177-179 °C. UV/Vis: λmax (ε) 535 (10184) 
nm. IR [cm-1]: ν 3306 (NH, w), 1690 (w), 1654 (s), 1610 (s), 1463 (s), 1321(s), 1174 (s), 1103 (m), 1036 
(m). 1H NMR [500 MHz]: δ 4.46 (2H, d, J = 5.5 Hz, H3''), 5.22 (1H, s, H1''a), 5.25 (1H, d, J = 5.0 Hz, 
H1''b), 5.86-5.92 (1H, m, H2''), 6.86 (1H, d, J = 8.0 Hz, H7'), 6.96 (1H, d, J = 8.0 Hz, H7), 7.00 (1H, t, J = 
8.0 Hz, H5), 7.12 (1H, t, J = 8.0 Hz, H5'), 7.28 (1H, t, J = 8.0 Hz, H6'), 7.49 (1H, t, J = 7.5 Hz, H6), 7.73 
(1H, d, J = 7.5 Hz, H4), 8.89 (1H, d, J = 8.0 Hz, H4'), 10.53 (1H, s, NH). 13C NMR [125 MHz]: δ 42.4 
(C3''), 106.6 (C3'), 108.8 (C7'), 112.1 (C7), 117.7 (C1''), 120.3 (C3a), 121.4 (C2), 121.8 (C5), 122.9 (C5'), 
125.5 (C4), 125.8 (C4'), 129.4 (C6'), 131.7 (C2''), 137.1 (C6), 139.6 (C3'a), 141.4 (C7'a), 151.9 (C7a), 
170.6 (C2'), 188.5 (C3). MS (EI): m/z 302 (M+, 100%). HRMS (ESI): calculated for C19H15N2O2: 
303.1134, found 303.1143.  
Further elution of the SiO2 flash column provided N,N'-diallylindirubin (14) (50.1 mg, 19%) as a blue 
solid. Mp 82-84 °C. UV/Vis: λmax (ε) 577 (4660
42) nm. IR [cm-1]: ν 1670 (s), 1603 (s), 1461 (s), 1328 (s), 
1173(s), 748.3 (s). 1H NMR [500 MHz]: δ 4.43 (2H, d, J = 5.0 Hz, H3''), 4.82 (2H, d, J = 6.0 Hz, H3'''), 
5.19-5.23 (3H, m, H1''a, H1''b, H1'''a), 5.28 (1H, d, J = 10.0 Hz, H1'''b), 5.84-5.89 (1H, m, H2''), 5.94-5.97 
(1H, m, H2'''), 6.82 (1H, d, J = 8.0 Hz, H7'), 7.02-7.09 (2H, m, H5, H5'), 7.12 (1H, d, J = 8.5 Hz, H7), 
7.25 (1H, t, J = 7.5 Hz, H6'), 7.53 (1H, t, J = 7.5 Hz, H6), 7.72 (1H, d, J = 7.5 Hz, H4), 8.63 (1H, d, J = 
7.5 Hz, H4'). 13C NMR [125 MHz]: δ 42.5 (C3''), 52.5 (C3'''), 108.7 (C7'), 110.9 (C3'), 112.5 (C7), 117.4 
(C1''), 118.6 (C1'''), 121.8 (C3'a), 122.0 (C5'), 122.4 (C3a), 122.6 (C5), 125.0 (C4), 125.6 (C4'), 129.7 
(C5'), 131.9 (C2''), 133.8 (C2'''), 136.6 (C6), 142.0 (C7'a), 142.4 (C2), 154.4 (C7a), 166.8 (C2'), 188.5 
(C3). MS (EI): m/z 342 (M+, 100%), 301 (M+-C3H5, 52). MS (ESI): 343 (M+H
+, 100%). HRMS (ESI): 
calculated for C22H19N2O2: 343.1447, found 343.1425.  
Further elution of the SiO2 flash column provided N-allylisatin (4) (29.0 mg, 10%) as an orange solid. Mp 
87-88 ºC (Lit.1 89-91 °C). UV/Vis: λmax (ε) 410 (435) nm. IR [cm
-1]: ν  2959 (w), 2919 (w), 2847 (w), 
1722 (s), 1601 (s), 1464 (s), 1348 (m), 1183 (w), 1085 (w), 925 (w), 760 (s). 1H NMR [500 MHz]: δ 4.37 
(2H, d, J = 5.5 Hz, H3'), 5.29-5.35 (2H, m, H1'), 5.82-5.88 (1H, m, H2'), 6.90 (1H, d, J = 8.0 Hz, H7), 
7.13 (1H, t, J = 8.0 Hz, H5), 7.57 (1H, t, J = 8.0 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4). 13C NMR [125 
MHz]: δ 42.7 (C3'), 111.1 (C7), 117.8 (C3a), 118.9 (C1'), 124.0 (C5), 125.6 (C4), 130.6 (C2'), 138.5 
(C6), 151.1 (C7a), 158.1 (C2), 183.5 (C3). MS (ESI): m/z 188 (M+H+, 100%). 
3.3.1.2. 2-Methylallyl 2-((2-methylallyl)amino)benzoate; (Z)-1'-(2-Methylallyl)-[2,3'-
biindolinylidene]-2',3-dione (10); (Z)-1,1'-bis(2-methylallyl)-[2,3'-biindolinylidene]-
2',3-dione (15); 1-allylindoline-2,3-dione (5).  
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was 
heated with caesium carbonate (600 mg, 1.84 mmol) and 3-bromo-2-methylpropene (224 μL, 2.22 mmol) 
for 16 h to obtain 2-methylallyl 2-((2-methylallyl)amino)benzoate as a colourless oil (12.8 mg, 7%). IR 
[cm-1]: ν 3371 (w), 2919 (m), 2845 (w), 1682 (s), 1222 (s). 1H NMR [500 MHz]: δ 1.79 (3H, s, H1''), 1.84 
(3H, s, H1'''), 3.78 (2H, s, H3), 4.70 (s, 2H, H3'), 4.89 (1H, s, H1a), 4.98 (2H, s, H1a', H1b), 5.07 (1H, s, 
H1b'), 6.59 (1H, t, J = 8.0 Hz, ArH3), 6.63 (1H, d, J = 8.5 Hz, ArH5), 7.33 (1H, t, J = 8.0 Hz, ArH4), 7.97 
(1H, d, J = 8.0 Hz, ArH2). 13C NMR [125 MHz]: δ 19.8 (C1''), 20.6 (C1'''), 49.0 (C3), 67.6 (C3'), 110.0 
(ArC1), 111.2 (C1''), 111.9 (ArC5), 112.8 (C1'''), 114.8 (ArC3), 131.7 (ArC2), 134.8 (ArC4), 140.5 (C2''), 
142.0 (C2'''), 151.6 (ArC6), 166.2 (C=O). MS (EI) m/z: 245 (M+, 63), 172 (100%). HRMS (EI) m/z: 
calculated for C15H19NO2: 245.1416; found 245.1415. 
Further elution of the SiO2 flash column provided (Z)-1'-(2-methylallyl)-[2,3'-biindolinylidene]-2',3-dione 
(10) (48.5 mg, 20%) as a red solid. Mp 154-156 °C. UV/Vis: λmax (ε) 536 (10339) nm. IR [cm
-1]: ν 3314 
(w), 2915 (w), 2845 (w), 1645 (s), 1604 (s), 1464 (s), 1316 (s), 1168 (s), 1082 (s). 1H NMR [500 MHz]: δ 
1.76 (3H, s, H1'''), 4.38 (2Η, s, H3''), 4.87 (1H, s, H1''a), 4.95 (1H, s, H1''b), 6.86 (1H, d,  J = 8.0 Hz, H7'), 
6.96 (1H, d, J = 8.0 Hz, H7), 7.00 (1H, t, J = 7.0 Hz, H5), 7.12 (t, J = 8.0 Hz, H5'), 7.26 (1H, t, J = 8.0 
Hz, H6'), 7.49 (1H, t, J = 7.5 Hz, H6), 7.72 (1H, d, J = 7.0 Hz, H4), 8.89 (1H, d, J = 7.5 Hz, H4'), 10.54 
(1H, s, NH). 13C NMR [125 MHz]: δ 20.2 (C1'''), 46.0 (C3''), 106.6 (C3'), 109.0 (C7'), 112.1 (C7), 112.8 
(C1''), 120.3 (C3a), 121.3 (C3'a), 121.8 (C5), 122.9 (C5'), 125.5 (C4), 125.7 (C4'), 129.4 (C6), 134.4 
(C2), 137.1 (C6), 139.5 (C2''), 141.6 (C7'a), 151.9 (C7a), 170.8 (C2'), 188.5 (C3). MS (EI): m/z 316 (M+, 
100%). HRMS (EI): calculated for C20H16N2O2: 316.1212, found 316.1218.  
Further elution of the SiO2 flash column provided (Z)-1,1'-bis(2-methylallyl)-[2,3'-biindolinylidene]-2',3-
dione (15) (85.1 mg, 30%) as a blue solid. Mp 88-90 °C. UV/Vis: λmax (ε) 580 (4957) nm. IR [cm
-1]: ν 
1666 (s), 1596 (s), 1464 (s), 1324 (s), 1168 (s), 1078 (s), 741 (s). 1H NMR [500 MHz]: δ 1.50 (3H, s, 
H1''''), 1.75 (3H, s, H1'''''), 4.35 (2H, s, H3'''), 4.81-4.91 (4H, m, H1''a, H1''b, H1'''a, H1'''b), 4.91 (2H, s, 
H3''), 6.80 (1H, d, J = 7.5 Hz, H7'), 7.03-7.06 (2H, m, H5, H5'), 7.08 (1H, d, J = 8.5 Hz, H7), 7.23 (1H, t, 
J = 7.5 Hz, H6'), 7.51 (1H, t, J = 8.0 Hz, H6), 7.72 (1H, d, J = 7.5 Hz, H4), 8.66 (1H, d, J = 8.0 Hz, H4'). 
13C NMR [125 MHz]: δ 19.9 (C1''''), 20.2 (C1'''''), 46.0 (C3''), 54.5 (C3'''), 108.8 (C7'), 111.0 (C3'), 112.3 
(C1''), 112.5 (C7), 114.9 (C1'''), 121.5 (C3'a), 121.9 (C5'), 122.3 (C3a), 122.5 (C5), 125.1 (C4), 125.6 
(C4'), 129.8 (C6'), 136.6 (C6), 139.1 (C2'''), 139.7 (C2''), 142.0 (C2), 142.3 (C7'a), 154.5 (C7a), 167.0 
(C2'), 188.6 (C3). MS (EI): m/z 370 (M+, 100%). HRMS (EI): calculated for C24H22N2O2: 370.1681, 
found 370.1686.  
Further elution of the SiO2 flash column provided 1-(2-methylallyl)indoline-2,3-dione (5) (8.0 mg, 3%) as 
an orange solid. Mp 87-88 ºC (Lit.3b Mp 87-88 °C). 1H NMR [500 MHz]: δ 1.77 (3H, s, H1''), 4.30 (2H, s, 
H3'), 4.98 (2H, d, J = 19.5 Hz, H1'), 6.89 (1H, d, J = 8.0 Hz, H7), 7.12 (1H, t, J = 7.5 Hz, H5), 7.56 (1H, 
t, J = 7.5 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4). 13C NMR [125 MHz]: δ 20.1 (C1''), 46.3 (C3'), 111.3 
(C7), 113.7 (C1'), 117.7 (C3a), 124.0 (C5), 125.5 (C4), 138.3 (C2'), 138.6 (C6), 151.3 (C7a), 158.3 (C2), 
183.4 (C3). MS (EI): m/z 201 (M+, 100%). 
3.3.1.3. (Z)-1'-(But-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (11); (Z)-1,1'-di(but-
2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione  (16).   
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was 
heated with caesium carbonate (600 mg, 1.84 mmol) and crotyl bromide (229 μL, 2.22 mmol) for 16 h to 
obtain (Z)-1'-(but-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (11) with a 2.3:1.0 ratio mixture of E:Z in 
the N'-side chain (119 mg, 49 %) as a red solid. Mp 190-192 °C. UV/Vis: λmax (ε) 535 (10711) nm. IR 
[cm-1]: ν 3306 (w), 2923 (w), 1646 (s), 1601 (s), 1459 (s), 1317 (s), 1165 (s), 1103 (s), 1072 (s), 743 (s). 
1H NMR [300 MHz]: δ 1.69 (3H, d, J = 6.0 Hz, H1''), 4.39 (2H, d, 5.5 Hz, H4''), 5.40-5.55 (1H, m, H3''), 
5.69-5.77 (1H, m, H2''), 6.89 (1H, d, J = 7.8 Hz, H7'), 6.96-7.03 (2H, m, H5, H7), 7.13 (1H, t, J = 7.5 Hz, 
H5'), 7.29 (1H, t, J = 8.0 Hz, H6'), 7.50 (1H, t, 7.4 Hz, H6), 7.73 (1H, d, J = 7.5 Hz, H4), 8.89 (1H, d, J = 
8.1 Hz, H4'), 10.56 (1H, s, NH). 13C NMR [75 MHz]: δ 17.9 (C1''), 41.8 (C4''), 108.6 (C3), 108.9 (C7'), 
112.2 (C7), 120.4 (C3'a), 121.5 (C3a), 121.9 (C5), 122.9 (C5'), 124.6 (C3''), 125.5 (C4), 125.8 (C4'), 
128.7 (C2''), 129.4 (C6'), 137.2 (C6), 139.6 (C5), 141.6 (C3'a), 151.6 (C3a), 170.6 (C2'), 188.6 (C3). MS 
(EI): m/z 316 (M+, 100%), 262 (M+-C4H6, 40). HRMS (ESI): calculated for C20H17N2O2: 317. 1290, 
found 317.1303. 
Further elution of the SiO2 flash column provided (Z)-1,1'-di(but-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-
dione (16) with a 5.5:1.0 ratio mixture of E:Z in the N-side chain and a 2.0:1.0 ratio mixture of E:Z in the 
N'-side chain (25.5 mg, 9%) as a blue solid. Mp 88-90 °C. IR [cm-1]: ν 2952 (w), 2914 (m), 2844 (w), 
1705 (s), 1606 (s), 1467 (s), 1356 (m), 1176 (m), 1081 (m), 752 (s). 
1H NMR [300 MHz]: δ 1.63-1.66 
(6H, m, H1'', H1'''), 4.36 (2H, d, J = 5.7 Hz, H4''), 4.76 (2H, d, J = 6.0 Hz, H4'''), 5.41-5.74 (4H, m, H3'', 
H3''', H2'', H2'''), 6.82 (1H, d, J = 8.7 Hz, H7'), 6.70-7.08 (2H, m, H5, H5'), 7.16 (1H, d, J = 8.1 Hz, H7), 
7.25 (1H, t, J = 7.8 Hz, H6'), 7.52 (1H, t, J = 8.1 Hz, H6), 7.70 (1H, d, J = 7.5 Hz, H4), 8.62 (1H, d, J = 
7.5 Hz, H4'). 13C NMR [75 MHz]: δ 17.9 (H1'''), 18.1 (H1''), 41.9 (H4'''), 52.0 (H4''), 108.7 (C7'), 110.9 
(C3), 112.7 (C7), 121.8 (C5'), 122.0 (C3a), 122.48 (C5'), 122.53 (C3'a), 124.8 (C4), 125.0 (C3''), 125.7 
(H4'), 126.3 (C3'''), 126.4 (C2'''), 129.7 (C6'), 130.4 (C2''), 136.6 (C6), 142.2 (C7'a), 142.5 (C2), 154.6 
(C7a), 166.8 (C2'), 188.7 (C3'). MS (EI): m/z 370 (M+, 100%), 315 (M+-C4H7, 56). HRMS (ESI): 
calculated for C24H23N2O2: 371.1760, found 371.1744. 
3.3.1.4. (Z)-1'-(3-Methylbut-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (12); (Z)-
1,1'-bis(3-methylbut-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (17).   
Following the general procedure A, a suspension of indirubin (209 mg, 798 μmol) in DMF (20 mL) was 
heated with caesium carbonate (624 mg, 1.91 mmol) and 3,3-dimethylallyl bromide (267 μL, 2.31 mmol) 
for 16 h to obtain (Z)-1'-(3-methylbut-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (12) as a red solid 
(76.4 mg, 29%). Mp 184-186 °C. UV/Vis: λmax (ε) 535 (10777) nm. IR [cm
-1]: ν 3316 (w), 2920 (w), 
1641 (s), 1600 (s), 1464 (s), 1350 (s), 1318 (s), 1166 (s), 1068 (s), 1036 (s), 742 (s). 
1H NMR [300 MHz]: 
δ 1.73 (3H, s, H1''), 1.86 (3H, s, H1'''), 4.41 (2H, d, J = 6.3 Hz, H4''), 5.22 (1H, t, J = 6.6 Hz, H3''), 6.83 
(1H, d, J = 8.1 Hz, H7'), 6.93-7.00 (2H, m, H5, H7), 7.10 (1H, t, J = 7.5 Hz, H5'), 7.47 (1H, t, J = 7.2 Hz, 
H6), 7.71 (1H, d, J = 7.5 Hz, H4), 8.86 (1H, d, J = 7.5 Hz, H4'), 10.53 (1H, s, NH). 13C NMR [75 MHz]: 
δ 18.5 (C1''), 26.0 (C1'''), 38.2 (C4''), 107.1 (C3'), 108.7 (C7'), 112.2 (C7), 118.8 (C2''), 120.4 (C3a), 
121.6 (C3'a), 121.8 (C5), 122.8 (C5'), 125.5 (C4), 125.9 (C4'), 129.4 (C6'), 137.0 (C2''), 137.2 (C6), 139.6 
(C2), 141.7 (C7'a), 152.0 (C7a), 170.5 (C2'), 188.6 (C3). MS (EI): m/z 330 (M+, 80), 262 (M+-C5H8, 
100%). HRMS (ESI): calculated for C21H19N2O2: 331.1447, found 331.1425.  
Further elution of the SiO2 flash column provided (Z)-1,1'-bis(3-methylbut-2-en-1-yl)-[2,3'-
biindolinylidene]-2',3-dione (17) (9.53 mg, 3%) as a blue solid. Mp: 92-94 °C. UV/Vis: λmax (ε) 578 
(5892) nm. IR [cm-1]: ν 2958 (w), 2917 (m), 2875 (w), 1673 (s), 1603 (s), 1460 (s), 1325 (s), 1163 (s), 
1071 (s), 742 (s). 
1H NMR [500 MHz]: δ 1.66 (3H, s, H1'''), 1.70 (3H, s, H1'''''), 1.71 (3H, s, H1''), 1.84 
(3H, s, H1''''), 4.41 (2H, d, J = 7.0 Hz, H4''), 4.82 (2H, d, J = 6.0 Hz, H4'''), 5.18-5.24 (2H, m, H3'', H3'''), 
6.90 (1H, d, J = 7.5 Hz, H7'), 7.02-7.06 (3H, m, H5, H5', H7), 7.25 (1H, t, J = 7.5 Hz, H6'), 7.51 (1H, t, J 
= 7.0 Hz, H6), 7.70 (1H, d, J = 7.0 Hz, H4), 8.61 (1H, d, J = 7.5 Hz, H4'). 13C NMR [125 MHz]: δ 18.4 
(C1'''), 18.5 (CH3'''), 25.8 (C1''), 25.9 (CH3''), 38.3 (C4'''), 48.1 (C4''), 108.5 (C7'), 108.7 (C3'), 112.5 (C7), 
119.1 (C3''), 120.2 (C3'''), 121.8 (C5'), 122.0 (C3'a), 122.4 (C5), 122.6 (C3a), 124.9 (C4), 125.6 (C4'), 
129.6 (C6'), 136.4 (C2'''), 136.5 (C6), 136.6 (C2''), 142.1 (C7'a), 142.6 (C2), 154.5 (C7a), 166.6 (C2'), 
188.9 (C3). MS (EI): m/z 398 (M+, 90), 329 (M+-C5H9, 57), 262 (M
+-C10H16, 100%). HRMS (ESI): 
calculated for C26H27N2O2: 399.2073, found 399.2060. 
3.3.1.5. (Z)-1'-Cinnamyl-[2,3'-biindolinylidene]-2',3-dione (13).   
Following the general procedure A, a suspension of indirubin (204 mg, 779 μmol) in DMF (20 mL) was 
heated with caesium carbonate (609 mg, 1.87 mmol) and cinnamyl bromide (450 mg, 2.26 mmol) for 16 
h to obtain (Z)-1'-cinnamyl-[2,3'-biindolinylidene]-2',3-dione (13) (61.8 mg, 21%) as a red solid. Mp 180-
182 °C. UV/Vis: λmax (ε) 535 (10159) nm. IR [cm
-1]: ν 3303 (w), 2920 (w), 2847 (w), 1638 (s), 1600 (s), 
1464 (s), 1356 (s), 1315 (s), 1169 (s), 1074 (s), 742 (s). 
1H NMR [300 MHz]: δ 4.58 (2H, d, J = 5.7 Hz, 
H3''), 6.22 (1H, dt, J = 15.9 Hz, J = 5.7 Hz, H2''), 6.59 (1H, d, J = 15.9 Hz, H1''), 6.87-6.99 (3H, m, H5, 
H7, H7'), 7.09 (1H, t, J = 7.8 Hz, H5'), 7.20-7.32 (6H, m, ArH2, ArH3, ArH4, ArH5, ArH6, H6'), 7.45 
(1H, t, J = 7.5 Hz, H6), 7.69 (1H, d, J = 7.2 Hz, H7'), 8.86 (1H, d, J = 7.5 Hz, H4'), 10.51 (1H, s, NH). 
13C NMR [75 MHz]: δ 42.1 (H3''), 106.8 (C3'), 108.9 (C7), 112.2 (C7'), 120.4 (C3a), 121.5 (C3'a), 121.9 
(C5), 123.0 (C2''), 123.3 (C5'), 125.6 (C4), 125.9 (C4'), 126.8 (ArC2, ArC6), 128.2 (C6'), 128.9 (ArC3, 
ArC5), 129.5 (Ar4), 133.1 (C1''), 136.5 (ArC1), 137.2 (C6), 139.7 (C2), 141.4 (C7'a), 151.9 (C7a), 170.7 
(C2'), 188.5 (C3). MS (EI): m/z 378 (M+, 86), 263 (M+-C9H7, 100%). HRMS (ESI): calculated for 
C25H19N2O2: 379.1447, found 379.1454.  
3.3.1.6. (Z)-1,1'-Dicinnamyl-[2,3'-biindolinylidene]-2',3-dione (18).  
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was 
heated with caesium carbonate (600 mg, 1.84 mmol) and cinnamyl bromide (443 mg, 2.22 mmol) for 4 h 
to obtain (Z)-1,1'-dicinnamyl-[2,3'-biindolinylidene]-2',3-dione (18) with a 1.0:1.1 ratio mixture of E:Z in 
the N-side chain and a 1.0:1.5 ratio mixture of E:Z in the N'-side chain (41.7 mg, 11%) as a blue solid. Mp 
89-93 °C. IR [cm-1]: ν 2917 (m), 1673 (s), 1603 (s), 1464 (s), 1325 (m), 1173 (s), 1084 (s), 739 (s). 
1H 
NMR [300 MHz]: δ 2.81 (2H, d, J = 7.2 Hz, H3'') 4.61 (2H, d, J = 6.0 Hz, H3'''), 6.21 (1H, dt, J = 15.9 
Hz, 5.7 Hz, H2''), 6.36 (1H, dt, J = 15.9 Hz, 5.7 Hz, H2'''), 6.59 (1H, d, J = 15.9 Hz, H1''), 6.63 (1H, d, J = 
16.2 Hz, H1'''), 6.88 (1H, d, J = 7.8 Hz, H7'), 7.04 (1H, t, J = 8.1 Hz, H5'), 7.10-7.32 (12H, m, ArH2, 
ArH2', ArH3, ArH3', ArH4, ArH4', ArH5, ArH5', ArH6, ArH6', H6', H7), 7.49 (1H, t, J = 7.8 Hz, H6), 
7.73 (1H, d, J = 7.8 Hz, H4), 8.65 (1H, d, J = 8.1 Hz, H4'). 13C NMR [75 MHz]: δ 40.8 (C3''), 42.2 (C3'''), 
108.9 (C7'), 111.0 (ArC), 112.7 (ArC), 121.9 (ArC), 122.1 (C5), 122.5 (ArC), 122.8 (C5'), 123.5 (C2'''), 
123.7 (C2''), 124.1 (ArC), 125.1 (C4), 125.8 (C4''), 126.5 (2 x ArC), 126.6 (ArC), 126.76 (2 x ArC), 
127.5 (ArC), 128.3 (ArC), 128.8 (2 x ArC), 129.9 (ArC), 131.4 (ArC), 132.8 (ArC), 134.1 (ArC), 136.8 
(C6), 142.1 (ArC), 143.1 (C7'a), 154.5 (C7a), 166.9 (C2), 178.8 (C2'), 188.6 (C3). MS (EI): m/z 494 (M+, 
40), 377 (M+-C9H9, 33), 362 (M+-C10H12, 100%). HRMS (ESI): calculated for C34H27N2O2: 495.2073, 
found 495.2080. 
3.3.1.7. Prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate; (Z)-1,1'-di(prop-2-yn-1-yl)-
[2,3'-biindolinylidene]-2',3-dione.  
Following the general procedure A, a suspension of indirubin (205 mg, 767 μmol) in DMF (20 mL) was 
heated with caesium carbonate (600 mg, 1.84 mmol) and propargyl bromide (443 mg, 2.22 mmol) for 16 
h to obtain prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate (13.2 mg, 8%) as a colourless solid. Mp 53-
54 ºC (Lit.5a 55-56 °C). 1H NMR [300 MHz]: δ 2.24 (1H, t, J = 2.7 Hz, H1''), 2.50 (1H, t, J = 2.7 Hz, 
H1'), 4.04 (2H, dd, J = 5.9 Hz, 2.4 Hz, H3''), 4.87 (2H, d, J = 2.4 Hz, H3'), 6.69 (1H, td, J = 7.5 Hz, 0.6 
Hz, H5), 6.80 (1H, d, J = 8.4 Hz, H3), 7.43 (1H, td, J = 8.0 Hz, 1.5 Hz, H4), 7.85 (1H, bs, NH), 7.97 (1H, 
dd, J = 8.1 Hz, 1.8 Hz, H6). 13C NMR [75 MHz]: δ 32.7 (C3''), 52.2 (C3'), 71.6 (C1''), 75.0 (C1'), 78.2 
(C2'), 79.8 (C2''), 110.4 (C1), 111.9 (C3), 116.1 (C5), 132.1 (C6), 135.3 (C4), 150.4 (C2), 167.8 (C=O). 
MS (ESI), m/z 214 (M+H+, 100%). HRMS (ESI): calculated for C13H12NO2: 214.0868, found 214.0860. 
Further elution of the SiO2 flash column provided (Z)-1,1'-di(prop-2-yn-1-yl)-[2,3'-biindolinylidene]-2',3-
dione (33.8 mg, 13%) as a blue solid. Mp 183-185 °C. UV/Vis: λmax (ε) 559 (4292) nm. IR [cm
-1]: ν 3261 
(w), 3234 (w), 1650 (s), 1606 (s), 1464 (s), 1330 (s), 1165 (s), 1076 (s), 1019 (m), 930 (m), 756 (s). 1H 
NMR [500 MHz]: δ 2.24 (1H, t, J = 2.0 Hz, H1''), 2.27 (1H, t, J = 2.0 Hz, H1'''), 4.62 (2H, d, J = 2.5 Hz, 
H3''), 5.02 (2H, d, J = 2.5 Hz, H3'''), 7.05 (1H, d, J = 8.0 Hz, H7'), 7.09-7.15 (2H, m, H5, H5'), 7.27 (1H, 
d, J = 8.0 Hz, H7), 7.34 (1H, t, J = 7.5 Hz, H6'), 7.61 (1H, t, J = 8.0 Hz, H6), 7.75 (1H, d, J = 7.0 Hz, 
H4), 8.70 (1H, d, J = 8.0 Hz, H4'). 13C NMR [125 MHz]: δ 29.5 (C3''), 39.5 (C3'''), 72.3 (C1''), 74.0 
(C1'''), 77.2 (C2''), 77.3 (C2'''), 108.9 (C7'),111.5 (C7'a), 112.6 (C7), 122.05 (C3'), 122.07 (C3'a), 122.6 
(C5), 123.1 (C5'), 125.1 (C4), 126.3 (C4'), 130.3 (C6'), 136.8 (C6), 141.2 (C7'a), 142.2 (C2), 153.7 (C7a), 
166.3 (C2'), 188.0 (C3). MS (EI): m/z 338 (M+, 100%), 299 (M+-C3H3, 78). HRMS (ESI): calculated for 
C22H15N2O2: 339.1134, found 339.1127. 
3.3.2. General Procedure B. 
A suspension of indirubin (1.0 eq.) in dry DMF (20 mL for 763 μmol) was sonicated for 5 min and then 3 
Ǻ molecular sieves (40.0 g for 763 μmol) were added. To the stirred solution was added caesium 
carbonate (2.4 eq.) and the reaction mixture was flushed with N2 and heated to 70 °C. The allyl bromide 
or an analogous derivative (4.7 eq.) was added and the reaction mixture was heated to 110 °C and stirred 
at this temperature for 6-24 h under an atmosphere of N2. The mixture was filtered while hot, washed 
with a little DMF and the filtrate concentrated under reduced pressure. The crude residue was subjected to 
flash silica gel column chromatography (gradient to CH2Cl2/petroleum spirit 4:1). 
3.3.2.1. Allyl 2-(allylamino)benzoate; 1,9a'-Diallyl-8'H-spiro[indoline-3,9'-pyrido[1,2-
a]indole]-2,10'(9a'H)-dione (19).   
Following the general procedure B, a suspension of indirubin (206 mg, 786 μmol) in DMF (20 mL) was 
heated with caesium carbonate (615 mg, 1.89 mmol) and allyl bromide (319 μL, 3.69 mmol) for 6 h to 
obtain allyl 2-(allylamino)benzoate as a colourless oil (11.6 mg, 7%). IR [cm-1]: ν 3364 (w), 3266 (m), 
2914 (w), 2848 (w), 1673 (m), 1232 (s), 1103 (s). 1H NMR [500 MHz]: δ 3.87 (2H, t, J = 5.5 Hz, H3), 
4.78 (2H, d, J = 6.0 Hz, H3'), 5.18 (1H, d, J = 10.5 Hz, H1a), 5.27 (1H, d, J = 9.0 Hz, H1b), 5.29 (1H, d, J 
= 15.3 Hz, H1a'), 5.40 (1H, d, J = 17.5 Hz, H1b'), 5.91-5.99 (1H, m, H2), 5.99-6.06 (1H, m, H2'), 6.59 
(1H, t, J = 7.5 Hz, ArH3), 6.66 (1H, d, J = 8.5 Hz, ArH5), 7.34 (1H, t, J = 7.8 Hz, ArH4), 7.86 (1H, bs, 
NH), 7.96 (1H, d, J = 8.0 Hz, ArH2). 13C NMR [125 MHz]: δ 45.5 (C3), 65.1 (C3'), 111.8 (ArC1), 114.9 
(ArC5), 116.3 (C1), 118.0 (C1'), 131.9 (ArC5), 132.8 (C2'), 134.5 (C2), 134.8 (ArC4), 151.3 (ArC6), 
168.5 (C=O). MS (ESI) m/z: 217 (M+H+, 100%). HRMS (ESI) m/z: calculated for C13H16NO2: 218.1181; 
found 218.1181. 
Further elution of the silica gel flash column provided 1,9a'-diallyl-8'H-spiro[indoline-3,9'-pyrido[1,2-
a]indole]-2,10'(9a'H)-dione (19) (210 mg, 70%) as a yellow solid. Mp 189-191 °C. UV/Vis: λmax (ε) 414 
(2014). IR [cm-1]: ν 1699 (s), 1605 (s), 1472 (m), 1361 (w), 1197 (w), 752 (s). 1H NMR [300 MHz]: δ 
2.06 (1Η, ddd, J = 18.3 Hz, 5.3 Hz, 1.8 Hz, H8'a), 2.74 (1H, dd, J = 13.7 Hz, 7.2 Hz, H3'''a), 3.00 (1H, dt, 
J = 18.3 Hz, 1.8 Hz, H8'b), 3.33 (1H, dd, J = 14.1 Hz, 6.9 Hz, H3'''b), 4.33 (1H, ddt, J = 15.9 Hz, 5.4 Hz, 
3.6 Hz, H3''a), 4.54-4.61 (1H, m, H3''b), 4.83 (1H, dd, J = 9.9 Hz, 2.4 Hz, H1'''a), 5.05 (1H, dd, J = 16.8 
Hz, 1.8 Hz, H1'''b), 5.02-5.41 (4H, m, H1''a, H1''b, H2''', H7'), 5.88-6.11 (1H, m, H2''), 6.57 (1H, t, J = 7.5 
Hz, H5), 6.68 (1H, t, J = 8.3 Hz, H2'), 6.74 (1H, d, J = 7.5 Hz, H7), 6.83 (1H, d, J = 7.2 Hz, H4), 7.00-
7.06 (3H, m, H6, H6', H4'), 7.24 (1H, d, J = 8.1 Hz, H1'), 7.45 (1H, t, J = 8.4 Hz, H3'). 13C NMR [75 
MHz]: δ 30.1 (C8'), 35.0 (C3'''), 42.8 (C3''), 48.0 (C3), 70.4 (C9'a), 103.3 (C1''), 107.8 (C4'), 108.9 (C7), 
117.5 (C2'''), 119.2 (C2'), 119.4 (C1'''), 121.8 (C5), 122.0 (C10'a), 122.5 (C6'), 124.3 (C1'), 124.7 (C4), 
128.2 (C6), 128.9 (C3a), 131.0 (C7'), 131.6 (C2''), 137.3 (C3'), 142.1 (C7a), 156.1 (C4'a),  175.6 (C2), 
199.1 (C10'). MS (EI): m/z 382 (M+, 74), 341 (M+-C3H5, 100%), 300 (M
+-C6H10, 51). HRMS (ESI): 
calculated for C25H23N2O2: 383.1760, found 383.1751. 
3.3.2.2. 7'-Methyl-1,9a'-bis(2-methylallyl)-8'H-spiro[indoline-3,9'-pyrido[1,2-
a]indole]-2,10'(9a'H)-dione (20).   
Following the general procedure B, a suspension of indirubin (205 mg, 782 μmol) in DMF (20 mL) was 
heated with caesium carbonate (612 mg, 1.88 mmol) and 3-bromo-2-methylpropene (370 μL, 3.68 mmol) 
for 6 h to obtain 7'-methyl-1,9a'-bis(2-methylallyl)-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-
2,10'(9a'H)-dione (20) (123 mg, 37%) as a yellow solid. Mp 212-214 °C. UV/Vis: λmax (ε) 435 (2274) nm. 
IR [cm-1]: ν 2969 (w), 2923 (w), 1690 (s), 1600 (s), 1476 (s), 1349 (m), 745 (s). 
1H NMR [500 MHz]: δ 
1.51 (3H, s, H1''''''), 1.85 (3H, s, H1''''), 1.89 (3H, s, H1'''''), 1.89 (1H, d, J = 18.0 Hz, H8'a), 2.68 (1H, d, J 
= 13.5 Hz, H3'''a), 2.98 (1H, d, J = 18.0 Hz, H8'b), 3.29 (1H, d, J = 14.0 Hz, H3'''b), 4.32 (1H, d, J = 16.0 
Hz, H3''a), 4.41 (1H, d, J = 16.0 Hz, H3''b), 4.59 (1H, s, H1'''a), 4.61 (1H, s, H1'''b), 4.97 (1H, s, H1''a), 5.02 
(1H, s, H1''b), 6.54 (1H, t, J = 7.5 Hz, H5), 6.60 (1H, t, J = 7.5 Hz, H2'), 6.74 (1H, d, J = 8.0 Hz, H7), 
6.78 (1H, d, J = 8.0 Hz, H4), 6.79 (1H, s, H6'), 6.95 (1H, d, J = 8.5 Hz, H4'), 7.01 (1H, t, J = 8.0 Hz, H6), 
7.20 (d, J = 7.5 Hz, H1'), 7.41 (1H, t, J = 7.0 Hz, H3'). 13C NMR [125 MHz]: δ 20.3 (C1''''), 20.4 (C1'''''), 
24.3 (C1''''''), 36.0 (C8'), 38.4 (C3'''), 46.8 (C3''), 49.0 (C3), 70.5 (C9'a), 107.8 (C4'), 109.3 (C7), 112.8 
(C1''), 113.2 (C7'), 116.2 (C1'''), 117.8 (C4), 118.8 (C2'), 122.1 (C5), 122.7 (C10'a), 124.5 (C1'), 124.9 
(C6'), 128.4 (C6), 129.3 (C3a), 137.4 (C3'), 139.4 (C2''), 139.8 (C2'''), 142.7 (C7a), 156.7 (C4'a), 176.1 
(C2), 199.6 (C10'). MS (EI): m/z 424 (M+, 30), 369 (M+-C4H7, 100%). HRMS (EI): calculated for 
C28H28N2O2: 424.2151, found 424.2150.  
3.3.2.3. (E)-1-(But-2-en-1-yl)-9a'-(but-3-en-2-yl)-8'-methyl-8'H-spiro[indoline-3,9'-
pyrido[1,2-a]indole]-2,10'(9a'H)-dione (21).   
Following the general procedure B, a suspension of indirubin (202 mg, 771 μmol) in DMF (20 mL) was 
heated with caesium carbonate (603 mg, 1.85 mmol) and crotyl bromide (373 μL, 3.62 mmol) for 6 h to 
obtain a fraction that was further purified by PTLC providing a mixture of at least two stereoisomers 
(arising from the cis/trans mixture in the double bond of the crotyl bromide starting material) of 1-(but-2-
en-1-yl)-9a'-(but-3-en-2-yl)-8'-methyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-2,10'(9a'H)-dione (21) 
(78.5 mg, 24%) as a yellow solid. Mp 154-160 °C. UV/Vis: λmax (ε) 411 (2211) nm. IR [cm
-1]: ν 1691 (s), 
1606 (s), 1470 (m), 1363 (w), 1337 (w), 748 (s). 
1H NMR [300 MHz]: δ 0.52 (3H, d, J = 8.0 Hz, H1''''), 
1.53 (3H, d, J = 7.3 Hz, H1'''''), 1.72 (3H, d, J = 7.3 Hz, H1''), 3.40-3.47 (2H, m, H8', H3'''), 4.33-4.46 
(2H, m, H4''), 4.64 (1H, dd, J = 10.0 Hz, 1.8 Hz, H1'''a), 4.86 (1H, dd, J = 17.0 Hz, 2.1 Hz, H1'''b), 5.03 
(1H, dd, J = 8.9 Hz, 2.3 Hz, H7'), 5.35-5.48 (1H, m, H2'''), 5.51-5.57 (1H, m, H3''), 5.72-5.89 (1H, m, 
H2''), 6.48 (1H, t, J  = 8.3 Hz, H5), 6.57 (1H, d, J = 7.8 Hz, H4), 6.67-6.76 (2H, m, H2', H4'), 7.01 (1H, t, 
J = 8.3 Hz, H6), 7.08-7.16 (3H, m, H1', H6', H7), 7.45 (1H, t, J = 7.8 Hz, H3'). 13C NMR [75 MHz]: δ 
15.6 (C1'''), 17.9 (C1''''), 18.0 (C1''), 34.6 (C8'), 42.6 (C4''), 43.3 (C3'''), 53.7 (C3), 73.6 (C9'a), 109.07 
(C6'), 109.12 (C4'), 110.9 (C7'), 116.0 (C1'''), 120.1 (C2'), 121.5 (C5), 123.9 (C10'a), 124.5 (C1'), 124.9 
(C3''), 125.2 (C7), 125.7 (C4), 127.2 (C3'a), 128.2 (C6), 129.3 (C2''), 136.8 (C3'), 139.6 (C2'''), 143.6 
(C7a), 157.5 (C4'a), 175.9 (C2), 200.0 (ArC10'). MS (EI): m/z 424 (M+, 26), 369 (M+-C4H7, 75), 315 
(M+-C4H6, 100%). HRMS (ESI): calculated for C28H29N2O2: 425.2229, found 425.2237.  
3.3.2.4. 1,9a'-Dicinnamyl-8'-phenyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-
2,10'(9a'H)-dione (22); 1-cinnamylindoline-2,3-dione (8).   
Following the general procedure B, a suspension of indirubin (205 mg, 782 μmol) in DMF (20 mL) was 
heated with caesium carbonate (612 mg, 1.88 mmol) and cinnamyl bromide (731 mg, 3.68 mmol) for 24 
h to obtain a fraction that was further purified by PLC providing two products, the first of which was 
1,9a'-dicinnamyl-8'-phenyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-2,10'(9a'H)-dione (22) (39.2 mg, 
8%), obtained as a yellow solid. Mp 118-120 °C. UV/Vis: λmax (ε) 414 (1659
42) nm. IR [cm-1]: ν 1701(s), 
1606 (s), 1470 (s), 1340 (w), 962 (w), 745 (s) 
1H NMR [300 MHz]: δ 3.17 (1H, ddd, J = 14.1 Hz, 7.8 Hz, 
1.2 Hz, H3'''a), 3.71 (1H, ddd, J = 13.5 Hz, 7.2 Hz, 1.2 Hz, H3'''b), 4.23 (1H, ddd, J = 16.4, 5.7 Hz, 1.8 Hz, 
H3''a), 4.52-4.61 (2H, m, H3''b, H8'), 5.30 (1H, dd, J = 8.0 Hz, 2.1 Hz, H7'), 5.74-5.85 (2H, m, H2''', H2''), 
6.23 (1H, d, J = 16.2 Hz, H1'''), 6.45-6.54 (1H, m, H1''), 6.68 (1H, t, J = 7.2 Hz, H2'), 6.87 (1H, t, J = 6.6 
Hz, H5), 6.9-7.30 (21H, m, ArH2, ArH3, ArH4, ArH5, ArH6, ArH2', ArH3', ArH4', ArH5', ArH6', 
ArH2'', ArH3'', ArH4'', ArH5'', ArH6'', H1', H4', H6', H4, H6, H7), 7.46 (1H, t, J = 7.7 Hz, H3'). 13C NMR 
[75 MHz]: δ 34.8 (C3'''), 42.3 (C3''), 45.2 (C8'), 53.7 (C3), 72.3 (C9'a), 107.8 (C7'), 108.3 (C1''), 109.1 
(C1'''), 119.9 (C5), 121.6 (C1''), 123.0 (ArC), 123.3 (C2'''), 123.4 (C2''), 123.5 (ArC), 124.9 (ArC), 125.7 
(ArC), 126.39 (2 x ArC), 126.44 (ArC), 126.7 (ArC), 126.8 (2 x ArC), 127.3 (ArC), 127.7 (2 x ArC), 
127.8 (ArC), 128.5 (ArC), 128.6 (2 x ArC), 128.7 (2 x ArC), 128.8 (ArC), 129.9 (2 x ArC), 132.3 (ArC), 
134.7 (ArC), 136.8 (ArC), 137.7 (ArC), 138.0 (ArC1), 142.9 (C7a), 156.1 (C4a), 175.2 (C2), 199.4 
(C10'). MS (EI): m/z 610 (M+, 90%), 493 (M+-C9H9, 100%), 375 (M
+-C18H19, 40%). MS (ESI): m/z 611 
(M+H+, 100%). HRMS (ESI): calculated for C43H35N2O2: 611.2699, found 611.2681. 
The second product separated from the above PTLC procedure was 1-cinnamylindoline-2,3-dione (8) 
(17.7 mg, 9%), obtained as an orange solid. Mp 108-110 °C. UV/Vis: λmax (ε) 424 (569) nm. IR [cm
-1]: ν 
1726 (s), 1601 (s), 1464 (m), 1366 (m), 1343 (m), 1165 (m), 762 (s). 1H NMR [300 MHz]: δ 4.53 (2H, d, 
J = 5.7 Hz, H3'), 6.18 (1H, dt, J = 5.7 Hz, J = 16.2 Hz, H2'), 6.68 (1H, d, J = 16.2 Hz, H1'), 6.96 (1H, d, J 
= 7.8 Hz, H7), 7.12 (1H, t, J = 7.8 Hz, H5), 7.25-7.37 (5H, m, ArH2, ArH3, ArH4, ArH5, ArH6), 7.56 
(1H, t, J = 7.8 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4). 13C NMR [75 MHz]: δ 42.5 (C3'), 111.2 (C7), 118.0 
(C3a), 121.8 (C2'), 124.1 (C5), 125.7 (C7), 126.8 (ArC3, ArC5), 128.5 (ArC4), 129.0 (ArC2, ArC6), 
134.4 (C1'), 136.0 (ArC1), 138.7 (C6), 151.1 (C7a), 158.2 (C2), 183.6 (C3). MS (EI): m/z 263 (M+, 
100%). HRMS (ESI): calculated for C17H14NO2: 264.1025, found 264.1012.  
3.3.2.5. Attempted allylation starting from N1'-allylindirubin.  
Following general procedure B, N1'-indirubin (9) (97.1 mg, 321 μmol) in DMF (8 mL) was heated with 
caesium carbonate (126 mg, 385 μmol) and allyl bromide (74.3 μL, 770 μmol) was added before being 
stirred for 20 h. Workup of the reaction produced an indefinable mixture of compounds with only the 
corresponding N-allylisatin detected by TLC analysis. 
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